Middle East and Africa Multiple Sclerosis Therapeutics Market

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027

Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce)

No. of Pages: 128
Report Code: TIPRE00022636
Category: Life Sciences
Middle East and Africa Multiple Sclerosis Therapeutics Market

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Data Triangulation and Validation

4. Middle East and Africa Multiple Sclerosis Therapeutics Market Landscape

4.1 Overview
4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Middle East and Africa Multiple Sclerosis Therapeutics Market – Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints

6. Middle East and Africa Multiple Sclerosis Therapeutics Market Regional Analysis

6.2 Middle East and Africa Multiple Sclerosis Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 Middle East and Africa Multiple Sclerosis Therapeutics Market Forecast Analysis

7. Middle East and Africa Multiple Sclerosis Therapeutics Market Analysis – by Drug Class

7.1 Immunosuppressant
  • 7.1.1 Overview
  • 7.1.2 Immunosuppressant: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Immunomodulators
  • 7.2.1 Overview
  • 7.2.2 Immunomodulators: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8. Middle East and Africa Multiple Sclerosis Therapeutics Market Analysis – by Route of Administration

8.1 Injectable
  • 8.1.1 Overview
  • 8.1.2 Injectable: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Oral
  • 8.2.1 Overview
  • 8.2.2 Oral: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9. Middle East and Africa Multiple Sclerosis Therapeutics Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Hospital Pharmacies: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Retail Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Retail Pharmacies: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 E-Commerce
  • 9.3.1 Overview
  • 9.3.2 E-Commerce : Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

10. Middle East and Africa Multiple Sclerosis Therapeutics Market – Middle East and Africa Analysis

10.1 Overview

10.2 Middle East and Africa
  • 10.2.1 Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
  • 10.2.1.1 Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.2.1.1 South Africa: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.2.1.1.1 South Africa: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
    • 10.2.1.1.2 South Africa: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
    • 10.2.1.1.3 South Africa: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel
  • 10.2.1.2 Saudi Arabia: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.2.1.2.1 Saudi Arabia: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
    • 10.2.1.2.2 Saudi Arabia: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
    • 10.2.1.2.3 Saudi Arabia: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel
  • 10.2.1.3 UAE: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.2.1.3.1 UAE: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
    • 10.2.1.3.2 UAE: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
    • 10.2.1.3.3 UAE: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel
  • 10.2.1.4 Rest of Middle East and Africa: Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.2.1.4.1 Rest of Middle East and Africa: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
    • 10.2.1.4.2 Rest of Middle East and Africa: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
    • 10.2.1.4.3 Rest of Middle East and Africa: Middle East and Africa Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments

13. Company Profiles

13.1 Merck & Co., Inc.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Novartis AG
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Bayer AG
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Sanofi
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 F. HOFFMANN-LA ROCHE LTD
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Biogen
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights
14.2 List of Abbreviations

The List of Companies - Middle East and Africa Multiple Sclerosis Therapeutics Market

  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen
  • Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)